Elosulfase alfa (Vimizim®) for the treatment of Morquio A syndrome

The National Health Care Institute carried out a reassessment of the medicinal product elosulfase alfa (Vimizim®).

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.